Morningstar[®] Document Research[™]

FORM 10-Q

CardioGenics Holdings Inc. - CGNH

Filed: September 14, 2012 (period: July 31, 2012)

Quarterly report with a continuing view of a company's financial position

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended July 31, 2012.

□ Transition report under Section 13 or 15(d) of the Exchange Act

For the transition period from ______ to _____.

Commission file number 000-28761

CARDIOGENICS HOLDINGS INC.

(Exact name of registrant as specified in its Charter)

Nevada (State or other jurisdiction of incorporation or organization) 88-0380546 (I.R.S. Employer Identification No.)

6295 Northam Drive, Unit 8 Mississauga, Ontario L4V 1WB (Address of Principal Executive Offices)

(905) 673-8501

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes No 🗆

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer and "smaller reporting company" in Rule 12b-2 or the Exchange Act. (Check one):

Accelerated Filer

Smaller Reporting Company

Large Accelerated filer

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes 🛛 No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No 🗖

As of September 7, 2012 the Registrant had the following number of shares of its capital stock outstanding: 31,449,239 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value \$0.0001, representing 14 exchangeable shares of the Registrant's subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,176,927 shares of the Registrant's Common Stock.

CARDIOGENICS HOLDINGS INC. FORM 10-Q For the Quarter Ended July 31, 2012 INDEX

Part I. Financial Information	Page 2
Item 1: Financial Statements (Unaudited)	2
Condensed Consolidated Balance Sheets at July 31, 2012 (Unaudited) and October 31, 2011	2
Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months ended July 31, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012	3
Condensed Consolidated Statement of Changes in Equity (Deficiency) (Unaudited) for the Nine Months ended July 31, 2012	4
Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months ended July 31, 2012 and 2011 and Cumulative from November 20, 1997 (Date of Inception) to July 31, 2012	5
Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Item 2: Management's Discussion and Analysis	10
Item 3: Quantitative and Qualitative Disclosures About Market Risk	14
Item 4: Controls and Procedures	14

Part II. Other Information	15
Item 1: Legal Proceedings	15
Item 1A: Risk Factors	16
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3: Defaults Upon Senior Securities	16
Item 4: Removed and Reserved	16
Item 5: Other Information	16
Item 6: Exhibits	16
Signatures	17
EX-31.1: CERTIFICATION EX-31.2: CERTIFICATION EX-32.1: CERTIFICATIONS	18 18 18

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

		July 31, 2012	_	October 31, 2011
Assets		(Unaudited)		(Note 2)
Current Assets				
Cash and Cash Equivalents	\$	72,732	\$	669,202
Accounts Receivable		256		9,002
Deposits and Prepaid Expenses		51,222		51,541
Refundable Taxes Receivable Investment Tax Credits Receivable		36,234 156,177		35,191 187,497
nivestinent fax credits Receivable		316,621		952,433
		510,021		
Property and Equipment, net		72,567		82,308
Patents, net		131,287		130,732
		203,854		213,040
Total Assets	\$	520,475	\$	1,165,473
Liabilities and Equity				
Current Liabilities				
Accounts Payable and Accrued Expenses	\$	646,059	\$	596,692
Funds Held in Trust for Redemption of Class B Common Shares	Ψ	4	Ψ	4
Current Portion of Capital Lease Obligation		7,490		25,711
Due to Shareholders		262,500		
		916,053		622,407
Long Term Liabilities				
Capital Lease Obligation, net of current portion		_		2,630
Total Liabilities		916,053	_	625,037
Commitments and Contingent Liabilities				
Equity Preferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and				
outstanding as at July 31, 2012 and October 31, 2011 Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239		—		—
and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares				
issued and outstanding as at July 31, 2012 and October 31, 2011 respectively		540		540
Additional paid-in capital		41,774,001		41,774,001
Deficit accumulated during development stage		(41,675,280)		(40,731,174)
Accumulated other comprehensive loss		(159,491)		(173,407)
Total CardioGenics Holdings Inc. equity		(60,230)		869,960
Non-controlling interest		(335,348)		(329,524)
Total equity (deficiency)		(395,578)		540,436
Total liabilities and equity	\$	520,475	\$	1,165,473

See notes to condensed consolidated financial statements.

]	For the three 1 July				For the nine n July			Cumulative From November 20, 1997 (Date of Inception) to July 31,
		2012		2011		2012		2011	 2012
Revenue	\$	-	\$	6,400	\$	1,136	\$	6,400	\$ 10,012
Operating Expenses Depreciation of Property and Equipment		4,541		5,409		13,635		14,938	215,074
Amortization of Patent Application Costs		1,215		1,090		3,775		3,222	16,186
Write-off of Patent Application Costs General and Administrative Write-off of Goodwill		154,869		278,314		516,357		958,963	214,625 8,105,047 12,780,214
Research and Product Development, Net of Investment Tax Credits Cost of Settlement of Lawsuit		73,715		141,206 1,753,800		422,453		534,776 1,753,800	 4,136,211 1,753,800
Total operating expenses Operating Loss		<u>234,340</u> (234,340)		2,179,819 (2,173,419)		<u>956,220</u> (955,084)		3,265,699 (3,259,299)	 <u>27,221,157</u> (27,211,145)
Other Expenses (Income) Interest Expense and Bank Charges, Net Loss on Change in Value of		5,402		6,440		14,887		15,340	2,151,523
Derivative Liability Loss (Gain) on Foreign Exchange		-		_		-		—	12,421,023
Transactions Total other expenses (income)	_	<u>(915)</u> 4,487	_	7,149		$\frac{(20,041)}{(5,154)}$	_	<u>139,312</u> 154,652	 <u> 189,224</u> <u> 14,761,770</u>
Loss from Continuing Operations		(238,827)		(2,187,008)		(949,930)		(3,413,951)	(41,972,915)
Discontinued Operations Gain on Sale of Subsidiary Loss from Discontinued Operations				(2.197.009)				(2 412 051)	 90,051 (127,762)
Net Loss Net Loss attributable to non-controlling interest		(238,827) (1,393)		(2,187,008) (14,638)		(949,930) (5,824)		(3,413,951) (22,850)	(42,010,626) (335,348)
Net Loss attributable to CardioGenics Holdings Inc.	\$	(237,434)	\$	(2,172,370)	\$	(944,106)	\$	(3,391,101)	\$ (41,675,278)
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc.	¢		¢		¢		¢		
Shareholders Weighted-average shares of Common Stock outstanding	\$	(0.01) 55,626,166	\$	(0.04) 54,626,166	\$	(0.02) 55,626,166	\$	(0.06) 54,256,408	

See notes to condensed consolidated financial statements.

CardioGenics Holdings Inc. (A Development Stage Company) Condensed Consolidated Statements of Changes in Equity (unaudited) For the nine months ended July 31, 2012

-	Common Shares	 nount	Additional Paid-in Capital			Deficit Accumulated During the Development Stage	Accumulated Other Comprehensive Income (Loss)	N	Noncontrolling Interest	Total Equity (Deficiency)
Balance October 31,					-					 · · · · ·
2011	55,626,166	\$ 540	\$	41,774,001	\$	(40,731,174)	\$ (173,407)	\$	(329,524)	\$ 540,436
Net loss attributable to noncontrolling interest Comprehensive Income (Loss):									(5,824)	(5,824)
Net Loss Other Comprehensive Income						(944,106)				(944,106)
Currency Translation Adjustment Total							13,916			 13,916
Comprehensive (Loss) Balance at July 31, 2012	55,626,166	\$ 540	\$	41,774,001	\$	(41,675,280)	\$ (159,491)	\$	(335,348)	\$ (930,190) (395,578)

See notes to condensed consolidated financial statements.

			ths En y 31,		Cumulative from November 20, 1997 (Date of Inception) To July 31,
		2012		2011	2012
Cash flows from operating activities Net Loss for the Period	\$	(949,930)	\$	(3,413,951)	¢ (42.010.626)
Adjustments to reconcile net loss for the period to net cash	Ф	(949,930)	Ф	(3,413,931)	\$ (42,010,626)
used in operating activities					
Depreciation of Property and Equipment		13,635		14,938	215,074
Amortization of Patent Application Costs		3,775		3,222	16,186
Write-off of Patent Application Costs		—		—	214,625
Write-off of Goodwill		—		—	12,780,214
Amortization of Deferred Debt Issuance Costs		—		—	511,035
Loss on Extinguishment of Debt		—		_	275,676
Loss on Change in Value of Derivative Liability Interest Accrued and Foreign Exchange Loss on Debt		_		_	12,421,023 922,539
Unrealized Foreign Currency Exchange Gains					25,092
Beneficial Conversion Charge included in Interest Expense		_		_	452,109
Re-pricing of Options for Services Rendered		_		163,750	163,750
Common Stock and Warrants issued on Settlement Of				,	,
Lawsuit		—		_	1,653,800
Common Stock Issued as Employee or Officer/Director					
Compensation		—		100.000	2,508,282
Common Stock Issued for Services Rendered		—		100,000	2,726,262
Stock Options Issued for Services Rendered		—		—	192,238
Stock Options Issued to Directors and Committee Chairman Changes in Operating Assets and Liabilities, Net of Acquisition		—		—	54,582
Accounts Receivable		8,746		(6,400)	(256)
Share Subscriptions Receivable				115,000	()
Deposits and Prepaid Expenses		319		38,673	(50,433)
Refundable Taxes Receivable		(1,043)		(16,101)	(35,370)
Investment Tax Credits Receivable		31,320		156,482	(136,115)
Accounts Payable and Accrued Expenses		49,370		1,835,883	(121,850)
Advances				(1.000.50.4)	131
Cash used in operating activities		(843,808)		(1,008,504)	(7,222,032)
Cash flows from investing activities					105.005
Cash Acquired from Acquisition		(2, 902)		(12, 772)	195,885
Purchase of Property and Equipment Patent Application Costs		(3,893) (4,329)		(12,772)	(223,559) (318,899)
Cash used in investing activities		(8,222)		(12,772)	(346,573)
Cash used in investing activities		(0,222)		(12,772)	(340,373)
Cash flows from financing activities					
Repayment of Capital Lease Obligations		(20,851)		(5,139)	(36,427)
Due to Shareholders		262,500		<u> </u>	262,500
Due to Director		—		(15,149)	725,330
Issue of Debentures		—		2 750	1,378,305
Issue of Common Shares on Exercise of Stock options Issue of Common Shares on Exercise of Warrants		_		2,750	2,781 45,652
Issue of Common Shares for Cash		_		359,411	5,624,169
Refund of Share Subscription		_		(15,378)	(15,000)
Redemption of 10% Senior Convertible Debentures		_		(15,575)	(394,972)
Cash provided by financing activities		241,649		326,495	7,592,338
Effect of foreign exchange on cash and cash equivalents		13,911		(32,327)	48,999

Source: CardioGenics Holdings Inc., 10-Q, September 14, 2012

Powered by Morningstar[®] Document ResearchSM

Cash and Cash Equivalents			
Increase (decrease) in cash and cash equivalents during the			
period	(596,470)	(727,108)	72,732
Beginning of Period	669,202	1,844,752	—
End of Period	\$ 72,732	<u>\$ 1,117,644</u> <u>\$</u>	72,732

See notes to condensed consolidated financial statements.

_

1.Nature of Business

CardioGenics Inc. ("CardioGenics") was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics' business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings Inc.

2.Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States ("US GAAP") as of July 31, 2012, its results of operations for the three and nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012, changes in equity for the nine months ended July 31, 2012 and cash flows for the nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012. CardioGenics Holdings Inc and its subsidiaries are referred to together herein as the "Company". Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2011 and 2010 (the "Audited Financial Statements") included in the Company's Form 10-K/A that was previously filed with the SEC on April 13, 2012 and from which the October 31, 2011 consolidated balance sheet was derived.

The results of the Company's operations for the three and nine months ended July 31, 2012 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2012.

The condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2012 of approximately \$41.7 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management's plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

3.Summary of Significant Accounting Policies.

Recent Accounting Pronouncements

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

4.Income Taxes

Based on the Company's evaluation, management has concluded that there are no significant tax reserves requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2012, approximated \$6,362,000 (2011 - \$5,495,000) which will expire from 2013 through 2032. All fiscal years have been assessed as originally filed in Canadian jurisdictions.

As of July 31, 2012, the Company had net operating loss carryforwards from US sources of approximately \$40,647,000 available to reduce future US Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2011 are yet to be filed.

For the nine months ended July 31, 2012 and 2011, the Company's effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

5.Due to Shareholders

In February 2012 the Company received \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers.

6.Stock Based Compensation

Stock-based employee compensation related to stock options for the nine months ended July, 2012 and 2011 amounted to \$-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

		Weighted Average Exercise
	Options	Price
Outstanding - October 31, 2010	305,000	\$ 2.34
Granted	_	_
Forfeited/Expired	_	_
Exercised	275,000	\$ 0.01
Outstanding - October 31, 2011	30,000	\$ 0.90
Granted	_	—
Forfeited/Expired	_	—
Exercised		—
Outstanding - July 31, 2012	30,000	\$ 0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2012.

7.Warrants

Outstanding warrants are as follows:

	July 31, 2012	October 31, 2011
Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to subscribers to the debenture financing of 2004 and its related extension	_	2,046,808
entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to	-	1,021,654
purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July	_	208,417
Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Common share $\int 0.000 \text{ provides and } \int 0.000 \text{ provides and } \int 0.000 \text{ provides } \int 0.0000 \text{ provides } \int 0.0000 \text{ provides } \int 0.000000000000000000000000000000000$	-	136,220
the Company at an exercise price of \$0.90 per share up to and including July 31, 2012 expired unexercised Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share	-	104,785
in the company at an exercise price of \$0.90 per common share up to and including July 31, 2017 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling	287,085	287,085
the holder to purchase 1 common share in the Company at an exercise price of \$0.30 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling	250,000	250,000
the holder to purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling	250,000	250,000
the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling	500,000	500,000
the holder to purchase 1 common share in the Company at an exercise price of \$1.00 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling	500,000	500,000
the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016 Issued to consultants in September 2011 entitling the holders to purchase 1 common	500,000	500,000
share in the Company at an exercise price of \$0.10 per common share up to and including March 20, 2013Issued to consultants in September 2011 entitling the holders to purchase 1 common	1,500,000	1,500,000
share in the Company at an exercise price of \$0.34 per common share up to and including March 20, 2013Issued to consultants in September 2011 entitling the holders to purchase 1 common	1,500,000	1,500,000
share in the Company at an exercise price of \$0.50 per common share up to and including March 20, 2013	1,000,000	1,000,000
Total Warrants outstanding	6,287,085	9,804,969

8.Issuance of Common Stock

During the nine months ended July 31, 2012, the Company issued no common shares, except for 211,977 common shares which were issued in exchange for 211,977 exchangeable shares.

9.Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Montl July 3		Nine Month July 3	
	2012	2011	2012	2011
Weighted-average shares - basic Effect of dilutive securities	55,626,166	54,626,166	55,626,166	54,256,408
Weighted-average shares - diluted	55,626,166	54,626,166	55,626,166	54,256,408

Basic EPS and diluted EPS for the three and nine months ended July, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 6,317,085 and 4,131,974 incremental shares respectively have been excluded from the nine months ended July 31, 2012 and 2011 computation of diluted EPS as they are antidilutive given the net losses generated.

10.Commitments and Contingent Liabilities

Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

11.Supplemental Disclosure of Cash Flow Information

	For the Nine Months Ended July 31					
		2012		2011		
Cash paid during the year for: Interest Income taxes	\$ \$	11,420	\$ \$	7,480		

Item 2. Management's Discussion and Analysis

You should read this Management's Discussion and Analysis ("MD&A") in combination with the accompanying unaudited condensed interim consolidated financial statements and related notes as well as the audited consolidated financial statements and the accompanying notes to the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") included within the Company's Annual Report on Form 10-K/A filed on April 13, 2012.

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed interim consolidated financial statements, which have been prepared in accordance with U.S. GAAP for interim financial statements filed with the Securities and Exchange Commission.

Critical Accounting Policies and Estimates

The preparation of these unaudited condensed interim consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, equipment, stock-based compensation, income taxes and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The accounting policies and estimates used as of October 31, 2011, as outlined in our previously filed Form 10-K/A, have been applied consistently for the nine months ended July 31, 2012.

Related Party Transactions

During the nine months ended July 31, 2012, we utilized advances from shareholders totaling \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers.

Off-Balance Sheet arrangements

We are not party to any off-balance sheet arrangements.

Results of operations

Nine months ended July 31, 2012 as compared to nine months ended July 31, 2011

	Nine Months Ended July 31,					
		2012		2011		\$ Change
Revenue	\$	1,136	\$	6,400	\$	(5,264)
Operating expenses: Depreciation of property and equipment Amortization of patent application costs General and administrative expenses Research and product development, net of investment tax credits Cost of settlement of lawsuit Total operating expenses Operating Loss Other expenses (income): Interest expense and bank charges, net Loss (gain) on foreign exchange		13,635 3,775 516,357 422,453 956,220 955,084 14,887 (20,041)		14,938 3,222 958,963 534,776 1,753,800 3,265,699 3,259,299 15,340 139,312		$(1,303) \\ 553 \\ (442,606) \\ (112,323) \\ (1,753,800) \\ (2,309,479) \\ (2,304,215) \\ (453) \\ (159,353) \\ (159,353)$
Net loss	\$	949,930	<u>\$</u>	3,413,951	\$	(2,464,021)

Revenues

During the nine months ended July 31, 2012 and 2011 we generated revenues of 2012 - \$1,136 and 2011 - \$6,400 respectively from sales of paramagnetic beads. We anticipate marginal additional revenues from said sales during the balance of the year.

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care ("POC") testing device; and, c) customize paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC for a disposable, single-use cartridge format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

	1	
L		

General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees and a charge of 2012 - Nil and 2011 - \$163,750 due to re-pricing of options.

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D and the inclusion of a Scientific Tax Credit from Canadian tax authorities of 2012 - \$60,000 and 2011 - Nil.

Cost of settlement of lawsuit

On August 17, 2011, the Company and Flow Capital Advisors Inc. participated in a court mandated mediation session wherein the parties agreed to a settlement of all claims. On August 23, 2011, the Company's Board of Directors approved the settlement. As a result, the financial statements at July 31, 2011 reflect a charge of \$1,753,800 for the cost of settlement of lawsuit.

Three months ended July 31, 2012 as compared to three months ended July 31, 2011

	Three Months Ended July 31,				
		2012		2011	 \$ Change
Revenue	\$	_	\$	6,400	\$ (6,400)
Operating expenses:					
Depreciation of property and equipment		4,541		5,409	(868)
Amortization of patent application costs		1,215		1,090	125
General and administrative expenses		154,869		278,314	(123,445)
Research and product development, net of investment tax credits		73,715		141,206	(67,491)
Cost of settlement of lawsuit				1,753,800	 (1,753,800)
Total operating expenses		234,340		2,179,819	(1,945,479)
Operating Loss		234,340		2,173,419	 (1,939,079)
Other expenses (income):					
Interest expense and bank charges, net		5,402		6,440	(1,038)
Loss (gain) on foreign exchange		(915)		7,149	 (8,064)
Net loss	\$	238,827	\$	2,187,008	\$ (1,948,181)

Revenues

During the three months ended July 31, 2012 and 2011 we generated revenues of 2012 - NIL and 2011 - \$6,400 respectively from sales of paramagnetic beads.

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care ("POC") testing device; and, c) customize paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC for a disposable, single-use cartridge format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees.

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The decrease in research and development expenses is attributable primarily to the decrease in staff engaged in R&D and the inclusion of a Scientific Tax Credit from Canadian tax authorities of 2012 - \$60,000 and 2011 - Nil.

Cost of settlement of lawsuit

On August 17, 2011, the Company and Flow Capital Advisors Inc. participated in a court mandated mediation session wherein the parties agreed to a settlement of all claims. On August 23, 2011, the Company's Board of Directors approved the settlement. As a result, the financial statements at July 31, 2011 reflect a charge of \$1,753,800 for the cost of settlement of lawsuit.

Liquidity and Capital Resources

We have not generated significant revenues since inception. We incurred a net loss of approximately \$950,000 and a cash flow deficiency from operating activities of approximately \$844,000 for the nine months ended July 31, 2012. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. We have funded our activities to date almost exclusively from debt and equity financings. These matters raise substantial doubt about our ability to continue as a going concern.

We will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our products, and to commence sales and marketing efforts. Our plans include financing activities such as private placements of our common stock and issuances of convertible debt instruments. We are also actively pursuing industry collaboration activities including product licensing and specific project financing.

We believe we will be successful in obtaining the necessary financing to fund our operations, meet revenue projections and manage costs; however, there are no assurances that such additional funding will be achieved and that we will succeed in our future operations.

Seasonality

We do not believe that our business is subject to seasonal trends or inflation. On an ongoing basis, we will attempt to minimize any effect of inflation on our operating results by controlling operating costs and whenever possible, seeking to insure that subscription rates reflect increases in costs due to inflation.

Recent Accounting Pronouncements

The FASB had issued certain accounting pronouncements as of July 31, 2012 that will become effective in subsequent periods; however, we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during the nine months ended July 31, 2012 and 2011 or that they will have a significant effect at the time they become effective.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

N/A.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2012, our management, including our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended ("Exchange Act"). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of July 31, 2012.

Management's Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate disclosure controls and procedures and internal control over financial reporting (as defined in the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, internal controls over financial reporting may not prevent or detect misstatements. The design and operation of a control system must also reflect that there are resource constraints and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls.

Our management assessed the effectiveness of our disclosure controls and procedures and internal control over financial reporting for the quarter ended July 31, 2012 based on the criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on such assessment, our management concluded that during the period covered by this report, our disclosure controls and procedures and internal control over financial reporting were not effective. Management has identified the following material weaknesses in our disclosure controls and procedures and internal control over financial reporting over financial reporting:

- lack of documented policies and procedures;
- there is no effective separation of duties, which includes monitoring controls, between the members of management; and,
- lack of resources to account for complex and unusual transactions.

Management is currently evaluating what steps, if any, can be taken in order to address these material weaknesses in light of our current management structure.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended July 31, 2012, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On April 22, 2009, CardioGenics was served with a statement of claim in the Province of Ontario, Canada, from a prior contractor claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in CardioGenics, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defence and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

On January 14, 2010, Flow Capital Advisors Inc. ("Flow Capital") filed a lawsuit against JAG Media Holdings Inc. in the Circuit Court of the 17th Judicial Circuit In and For Broward County Florida (Case No. 10001713) (the "Flow Capital State Action"). Pursuant to this lawsuit, Flow Capital alleges that JAG Media Holdings breached a Non-Circumvention Agreement it had entered into with Flow Capital, dated January 1, 2004.

On January 15, 2010 Flow Capital filed a lawsuit against CardioGenics Inc., and another defendant in the United States District Court for the Southern District of Florida, Fort Lauderdale Division (Case No. 10-CV-60066-Martinez-Brown) (the "Flow Capital Federal Action"). This lawsuit alleges that CardioGenics (i) breached a Finder's Fee Agreement in connection with the CardioGenics Acquisition; and (ii) breached a non-circumvention agreement. Flow Capital is claiming that it is entitled to the finder's fee equal to eight percent (8%) of the JAG Media Holdings shares received by CardioGenics, or the equivalent monetary value of the stock. Plaintiff subsequently amended its complaint to add related tort claims.

Pursuant to applicable federal court rules, the parties to the Flow Capital Federal Action participated in a court mandated mediation session on August 17, 2011 where the parties attempted to settle their disputes. At the mediation, the parties agreed to a settlement of all claims as described below, subject to the approval of the Board of Directors of CardioGenics Holdings Inc., which approval was subsequently obtained. Pursuant to the settlement agreement, Flow Capital agreed to dismiss, with prejudice, the Flow Capital Federal Action and the Flow Capital State Action and CardioGenics agreed to issue Flow Capital 1,000,000 shares of restricted CardioGenics Holdings common stock and warrants to purchase restricted CardioGenics Holdings common stock as follows:

Type of Warrant	Number of Shares	Exercise Price	Vesting Date	Term
Cash Exercise Only	250,000	\$0.30/share	immediate	5 years
Cash Exercise Only	250,000	\$0.50/share	immediate	5 years
Cash Exercise Only	500,000	\$0.75/share	immediate	5 years
Cash Exercise Only	500,000	\$1.00/share	immediate	5 years
Cash or Cashless Exercise	500,000	\$0.75/share	August 1, 2012	5 years

The restricted shares of common stock and the warrants are subject to the rights and restrictions of Rule 144 and do not have any registration rights. As part of the settlement, the parties also exchanged mutual general releases and CardioGenics Holdings agreed to pay Flow Capital, in three monthly installments, \$100,000 for Flow Capital's legal fees.

On August 23, 2011, the Company's Board of Directors approved the settlement. As a result, the Company recorded a charge to the Condensed Statement of Operations at July 31, 2011 of \$1,753,800 for Cost of Settlement of Lawsuit, which amount is included in Accounts Payable and Accrued Expenses at July 31, 2011.

On October 26, 2010 Karver International Inc. filed a lawsuit in the 11th Judicial Circuit in and for Miami-Dade County, Florida against CardioGenics Holdings Inc. and several other defendants including affiliates, officers and directors of CardioGenics Holdings, Inc. The Plaintiff generally alleges that the named defendants made certain alleged misrepresentations in connection with the purchase of shares of CardioGenics Holdings Inc. On December 20, 2010 CardioGenics Holdings Inc. and other defendants filed a motion to dismiss on the basis that the court lacks personal jurisdiction over most defendants, that an enforceable forum selection clause requires that the action be litigated in Ontario, Canada that the doctrine of *forum non conveniens* requires dismissal in favor of the Ontario forum, and that the complaint suffers from numerous other technical deficiencies warranting dismissal (e.g., failure to attach documents to the Complaint, failure to plead fraud with particularity, etc.). In addition, prior to the motion being heard, Karver's attorney filed a motion to withdraw as counsel for Karver. The court granted Karver's attorney's motion to withdraw and Karver had until approximately April 26, 2011 to engage new counsel. On April 20, 2011, having not engaged new counsel as of that date, Karver filed with the court a Notice of Voluntary Dismissal Without Prejudice, which dismisses the lawsuit against the named defendants without prejudice to Karver's rights to recommence the action.

Item 1A. Risk Factors

Not Applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. (Removed and Reserved)

None

Item 5. Other Information

None

Item 6. Exhibits

31.1Section 302 Certification of Chief Executive Officer.

31.2Section 302 Certification of Chief Financial Officer.

32.1Section 906 Certification of Chief Executive Officer and Chief Financial Officer.

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CARDIOGENICS HOLDINGS INC.

Date: September 14, 2012	By:	/s/ Yahia Gawad Name: Yahia Gawad Title: Chief Executive Officer
Date: September 14, 2012	By:	/s/ James Essex Name: James Essex Title: Chief Financial Officer

EXHIBIT INDEX

- 31.1Section 302 Certification of Chief Executive Officer
- 31.2Section 302 Certification of Chief Financial Officer

32.1Section 906 Certification of Chief Executive Officer and Chief Financial Officer

SECTION 302 CERTIFICATION

I, Yahia Gawad, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended July 31, 2012 of CardioGenics Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in the report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: September 14, 2012

/s/ Yahia Gawad Yahia Gawad Chief Executive Officer

SECTION 302 CERTIFICATION

I, James Essex, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended July 31, 2012 of CardioGenics Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in the report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: September 14, 2012

/s/ James Essex James Essex Chief Financial Officer

Section 906 Certification by the Chief Executive Officer and Chief Financial Officer

Each of Yahia Gawad, Chief Executive Officer, and James Essex, Chief Financial Officer, of CardioGenics Holdings Inc., a Nevada corporation (the "Company") hereby certifies pursuant to 18 U.S.C. ss. 1350, as added by ss. 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge:

(1) The Company's periodic report on Form 10-Q for the period ended July 31, 2012 ("Form 10-Q") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operation of the Company.

/s/ Yahia Gawad

/s/ James Essex

Name: Yahia Gawad Title: Chief Executive Officer

Date: September 14, 2012

Name: James Essex Title: Chief Financial Officer

Document and Entity Information

Document and Entity Information (USD \$)	9 Months Ended 07/31/2012	09/07/2012
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	2012-07-31	
Document Fiscal Year Focus	2,012	
Document Fiscal Period Focus	Q3	
Trading Symbol	CGNH	
Entity Registrant Name	CARDIOGENICS HOLDINGS INC.	
Entity Central Index Key	0001089029	
Current Fiscal Year End Date	10-31	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		31,449,239

Condensed Consolidated Balance Sheets

Additional Paid In Capital [Member]International Capital Action of Control State (Member)International Capital Action of C	Condensed Consolidated Balance Sheets (USD \$)	07/31/2012	10/31/2011
Aquantial query (deficiency)\$ 44,075.200\$ 44,075.200\$ 44,075.200Carling query (deficiency)(19.09)(19.09)(19.09)(19.09)Addream Park In Capital Identified	Accumulated Deficit During Development Stage [Member]		
Assemulated Outer Comprehensive Insome [Member] Function Second	Equity		
FapingIteration of the second of	Total equity (deficiency)	<u>\$ (41,675,280)</u>	<u>\$ (40,731,174)</u>
Indequip (definiency)(159.40)(159.40)Addinoant Paid In Capital (Member)IIFapiry41.775.0041.775.0041.775.00Colla qualy (definiency)41.775.0041.775.00IFapiryIIITotal qualy (definiency)IIINencomolling Interest (Member)IIIFapiryIIIITotal qualy (definiency)IIIIStatistic (Member)IIIICartent AssetIIIICastend Cach EquivalentsIIIIDepoisits and Propaga ExpensesIIIIIIIIIDepoisits and Propaga ExpensesIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Accumulated Other Comprehensive Income [Member]		
Additional Paid In Quantization of Control Statution of	Equity		
EquipImage in the set of the s	Total equity (deficiency)	<u>(159,491)</u>	(173,407)
Indequip (deficiency)4,1,72,4014,1,72,4014,1,72,401Common Stock [Member]FauitFauitFauitSouthSouthSouthRouting (deficiency)SouthSouthSouthNoncontrolling Interest [Member]SouthSouthSouthCarling (deficiency)SouthSouthSouthSouthRouting (deficiency)SouthSouthSouthSouthSouthConcent Julie (deficiency)SouthSouthSouthSouthSouthCarlen AussiSouthSouthSouthSouthSouthSouthAccurate SouthSouthSouthSouthSouthSouthSouthCarlen AussiSouthSouthSouthSouthSouthSouthReindwich ExcercivableSouthSouthSouthSouthSouthSouthActivate ReceivableSouthSouthSouthSouthSouthSouthAssets, Noncurent, TotalSouthSouthSouthSouthSouthSouthSouth BayesSouthSouthSouthSouthSouthSouthSouthSouthCorrent Motion Corputal ExcercivableSouth </td <td>Additional Paid In Capital [Member]</td> <td></td> <td></td>	Additional Paid In Capital [Member]		
Common Stock [Member]Select and the select and the selec	Equity		
PaintPaintTotal quiy (deficiency)540Noncorriling Interest (Member]Equity(353.48)Calla quiy (deficiency)(353.48)Accorre Accorre A	Total equity (deficiency)	<u>41,774,001</u>	<u>41,774,001</u>
Note optimities (Member)549RegiveInterest (Member)EquiveStatus (Status)Total equive (Member)Status)Status (Member)Status)Corrent AssonInterest (Member)Carrent Asson2023 (Status)Carrent Asson2023 (Status)Constand Cash Equivalents2030 (Status)Accounts Receivable2030 (Status)Constand Receivable31662 (Status)Carrent Asson31662 (Status)Deposition Prepaid Expenses31662 (Status)Refundable Taxes Receivable31663 (Status)Incestment Tax Credits Receivable31663 (Status)Assets, Current, Total31662 (Status)Patents, net31663 (Status)Assets, Nourrent, Total31663 (Status)Total Assets32047 (Status)Current Portion of Class Receivable32047 (Status)Coursent Payable and Accound Expense4Coursent Portion of Class Receivable32047 (Status)Coursent Portion Class Receivable32047 (Status)Cours	Common Stock [Member]		
Nonontrolling Interest (Member)Second Second Se	Equity		
Nonontrolling Interest (Member)Second Second Se	Total equity (deficiency)	540	<u>540</u>
PaperlyPerformPerformTotal equity (deficiency)(355 348)(355 348)Assets(355 348)(355 348)AssetsCarrent Assets(72,72)(69,00)Caronal Cash Equivalents(72,72)(69,00)Accourats Receivable(72,72)(73,72)(73,72)Refindable Taxes Receivable(36,23)(35,19)Investment Tax Credits Receivable(36,23)(35,19)Investment Tax Credits Receivable(36,23)(35,19)Investment Tax Credits Receivable(36,23)(35,19)Property and Fapipment, net(36,23)(35,19)Property and Fapipment, net(31,28)(31,30)Assets, Noncurrent, Total(31,28)(31,30)Total Assets(31,28)(31,30)Total Assets(31,28)(31,30)Total Assets(31,28)(31,30)Total Assets(31,28)(31,30)Total Assets(31,30)(31,30)Total Assets(31,30)(31,30)Total Assets(31,30)(31,30)Carrent Ottion(31,30)(31,30)Total Assets(31,30)(31,30)Fubilities and Equiption of Class IS Common Shares(31,60)Current Portion of Class IS Common Shares(41,60)Current Portion of Class IS Common Shares(31,60)Current Portion of Class IS Common Shares(31,60)Current Portion for Current portion(31,60)Current Portion Class IS Common Shares and Unity IS (21,60)(31,60)Current P			
Idla quiju (deficiency)(33.5.34)			
AsetsCurrent AssetsCash and Cash Equivalents72,732669,20Accounts Receivable72,732659,20Deposits and Prepaid Expenses51,22251,54Refundable Taxes Receivable156,217187,49Investment Tax Credits Receivable156,177187,49Assets, Current, Total316,621925,433Property and Equipment, net316,621925,433Property and Equipment, net316,621923,324Assets, Noncurrent, Total131,287313,034Assets, Noncurrent, Total203,825313,044Total Assets203,825313,044Total Assets520,475313,044Total Assets520,475316,621Property and Equipment, net520,475313,044Total Assets646,059906,052313,044Total Assets646,059906,052306,069Funds Held in Trust for Redemption of Class B Common Shares4-Current Ortion of Capital Lease Obligation202,500202,500Loa to Sharcholders202,500202,500202,500Loa to Sharcholders202,500202,500202,500Current Total Lease Obligation, net of current portion204,500205,500Total Labilities916,052625,500625,500Total Labilities916,052625,500625,500Total Labilities916,052625,500625,500Total Labilities916,052625,500625,500Total Labilitie	Total equity (deficiency)	(335,348)	(329,524)
Cash and Cash Equivalents72,732669.20Accounts Receivable2569,00Deposits and Prepaid Expenses51,22251,54Refundable Taxes Receivable36,23435,19Investment Tax Credits Receivable166,1771187,49Assets, Current, Total31,622925,43Property and Equipment, net20,355213,047Assets, Noncurrent, Total20,355213,047Total Assets20,355213,047Total Assets20,35521,155,47Labilities and Equity20,35521,155,47Current Liabilities20,35711,155,47Accounts Payable and Accrued Expenses646,05959,669Funds Held in Trust for Redemption of Class B Common Shares47Current Liabilities20,250022,25022,250Funds Held in Trust for Redemption of Class B Common Shares47Current Dorion of Capital Lease Obligation20,250022,250Current Distilites20,250022,250022,250Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,250026,2500Current Liabilities21,65126,2500<		<u>, </u>	<u> </u>
Accounts Receivable 256 9,00 Deposits and Prepaid Expenses 51,222 51,54 Refundable Taxes Receivable 36,234 35,19 Investment Tax Credits Receivable 166,21 922,43 Property and Equipment, net 216,621 922,43 Property and Equipment, net 203,854 213,047 Assets, Noncurrent, Total 203,854 213,042 Total Assets 220,355 21,054,27 Iabilities and Equipment, net 203,854 21,054,27 Labilities and Equipment, Total 203,854 21,054,27 Intrast Scottant Expenses 646,059 596,69 Funds Held in Trust for Redemption of Class B Common Shares 4 7 Accounts Payable and Accrued Expenses 646,059 596,69 Funds Held in Trust for Redemption of Class B Common Shares 4 7 Current Portion of Capital Lease Obligation 262,200 262,200 Iabilities, Current, Total 262,200 262,200 Capital Lease Obligation, net of current portion 261,300 262,300 Capitan Liabilities	Current Assets		
Accounts Receivable 256 9,00 Deposits and Prepaid Expenses 51,222 51,54 Refundable Taxes Receivable 36,234 35,19 Investment Tax Credits Receivable 166,21 922,43 Property and Equipment, net 216,621 922,43 Property and Equipment, net 203,854 213,047 Assets, Noncurrent, Total 203,854 213,042 Total Assets 220,355 21,054,27 Iabilities and Equipment, net 203,854 21,054,27 Labilities and Equipment, Total 203,854 21,054,27 Intrast Scottant Expenses 646,059 596,69 Funds Held in Trust for Redemption of Class B Common Shares 4 7 Accounts Payable and Accrued Expenses 646,059 596,69 Funds Held in Trust for Redemption of Class B Common Shares 4 7 Current Portion of Capital Lease Obligation 262,200 262,200 Iabilities, Current, Total 262,200 262,200 Capital Lease Obligation, net of current portion 261,300 262,300 Capitan Liabilities	Cash and Cash Equivalents	72 732	669 202
Deposits and Prepaid Expenses51,22251,54Refundable Taxes Receivable36,23335,19Investment Tax Credits Receivable156,177187,49Assets, Current, Total31,6621952,433Property and Equipment, net72,56782,300Patents, net131,287130,73Assets, Noncurrent, Total203,854213,043Total Assets203,854213,043Total Assets520,4751,165,477Liabilities and Equipment, net520,4751,165,477Current Liabilities and Equip520,4751,165,477Current Liabilities and Equip520,4751,165,477Current Liabilities and Equip646,659596,697Funds Held in Trust for Redemption of Class B Common Shares64596,697Liabilities, Current, Total Lease Obligation74,90252,710Liabilities262,503622,403262,503Common stocholers262,503562,503Common stoch part value S,0001 per share, 5,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 2,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31,2012 and October 31,2011 respectived.54			,
Refindable Taxes Receivable36,23435,19Investment Tax Credits Receivable156,177187,49Assets, Current, Total316,621952,433Property and Equipment, net72,56782,300Patents, net131,287130,737Assets, Noncurrent, Total203,884213,044Total Assets203,0251165,477Liabilities and Equipment, net203,884213,044Total Assets203,0251165,477Liabilities and Equipment, Total203,884213,044Total Assets204,0571165,477Liabilities and Equipment, Total203,884213,044Current Liabilities646,059596,694Funds Held in Trust for Redemption of Class B Common Shares44Current Ortion of Capital Lease Obligation204,203204,204Liabilities916,053622,404204,204Liabilities916,053622,404204,204Liabilities916,053622,404204,204Common stock par value S,000,000 shares authorized, 1 issued and outstanding as at July 31,2012 and October 31,2017,822,0000 shares authorized, 31,449,239 and 31,237,262 common shares and 21,769,27 and 24,388,944 exchangeable shares issued and outstanding as at July 31,2012 and October 31,2017,822,834545,434			51,541
Investment Tax Credits Receivable1156,1771157,49Assets, Current, Total316.621952.433Property and Equipment, net712,6782,30Patents, net131,287130,73Assets, Noncurrent, Total203.854213.043Total Assets520.4751.165.477 Liabilities and Equipment , Total520.4751.165.477Current Liabilities520.4751.165.477Current Liabilities646.059596.69Funds Held in Trust for Redemption of Class B Common Shares646.059596.69Funds Held in Trust for Redemption of Class B Common Shares74.9025.71Due to Shareholders262.40074.9025.71Liabilities, Current, Total916.053622.400Due to Shareholders262.503622.400Liabilities, Current, Total916.053625.033Total Liabilities916.053625.033Common stock part value S.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as al July 31, 2012 and October 31, 2017, espectively54Current 24, 716, 927 and 24,388,944 exchangeable shares issued and outstanding as al July 31, 2012 and Corber 31, 2017, espectively54			35,191
Assets, Current, Total316.62932.43Property and Equipment, net72,5682,30Patents, net131.287130,73Assets, Noncurrent, Total203.854213.04Total Assets520.4751.165.477 Liabilities and Equity 520.4751.165.477Current Liabilities646.059596.69Funds Held in Trust for Redemption of Class B Common Shares64596.69Funds Held in Trust for Redemption of Class B Common Shares7477.90Lue to Shareholders262,501262,501262,501Luibilities, Current, Total916.053622,400Luibilities, Current, Total916.053622,400Luibilities, Current, Total916.053622,400Luibilities, Current, Total916.053625,033Controt and Contingent Liabilities916.053625,033Total Labilities916.053625,033Total Liabilities916.053625,033Common store, iz par value S,000,00 shares authorized, 1,1449,239 and 31,237,262 common shares and S,1449,239 and 31,237,262 common shares and S,1449,338,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively54	Investment Tax Credits Receivable		187,497
Patents, net131,287130,73Assets, Noncurrent, Total203,854213,04Total Assets520,4751,165,47Liabilities and Equity21Accounts Payable and Accrued Expenses646,059596,69Funds Held in Trust for Redemption of Class B Common Shares45Current Vortion of Capital Lease Obligation45Due to Shareholders262,500262,500Liabilities, Current, Total916,053622,400Long Term Liabilities916,053622,400Contrant Liabilities916,053622,400Contrant Itabilities916,053622,500Comminents and Contingent Liabilities916,053625,033Comminents and Contingent Liabilities916,053625,033Prefreg stock, par value \$,00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540	Assets, Current, Total	<u>316,621</u>	952,433
Assets, Noncurrent, Total203.84213.04Total Assets520.4751,165.47Liabilities and Equity520.4751,165.47Current Liabilities646.059596.69Funds Held in Trust for Redemption of Class B Common Shares646.059596.69Funds Held in Trust for Redemption of Class B Common Shares7,49025,71Due to Shareholders262,500262,500622,400Liabilities, Current, Total916.053622,400625,033Long Tern Liabilities916.053625,033625,033Total Lease Obligation, net of current portion916.053625,033625,033Comminents and Contingent Liabilities916.053625,033625,033Ferferred stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 545424,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2011 respectively54	Property and Equipment, net	72,567	82,308
Total Assets 520,475 1,165,47 Liabilities and Equity 520,475 1,165,47 Current Liabilities Current Liabilities 520,475 1,165,47 Accounts Payable and Accrued Expenses 646,059 596,69 596,69 Funds Held in Trust for Redemption of Class B Common Shares 4 520,270 596,69 Funds Held in Trust for Redemption of Class B Common Shares 7,490 25,71 Due to Shareholders 262,500 502,240 Liabilities, Current, Total 916,053 622,400 Long Tern Liabilities 916,053 622,503 Contral Lease Obligation, net of current portion 916,053 625,033 Total Liabilities 916,053 625,033 Commitments and Contingent Liabilities 916,053 625,033 Commitments and Contingent Liabilities 916,053 625,033 Feferred stock; par value \$,0001 per share; 5,000,000 shares authorized, 31,492,393 and 31,237,262 common shares and 2,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31,2012 and October 31, 2011 respectively 54	Patents, net	131,287	130,732
Liabilities and EquityImage: Participant of the system of the	Assets, Noncurrent, Total	203,854	<u>213,040</u>
Current Liabilities 646.059 596.69 Funds Held in Trust for Redemption of Class B Common Shares 4 4 Current Portion of Capital Lease Obligation 7,490 25,711 Due to Shareholders 262,500 262,500 Liabilities, Current, Total 916.053 622,400 Cong Term Liabilities 916.053 625,000 Condition, net of current portion 26,500 625,000 Conditities, Current, Total 916.053 625,000 Conditities 916.053 625,000 Commitments and Contingent Liabilities 916.053 625,000 Feferer dstock; par value \$.00001 per share, 5,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31,2012 and October 31, 2011 respectively 54	Total Assets	<u>520,475</u>	<u>1,165,473</u>
Accounts Payable and Accrued Expenses6646,059596,69Funds Held in Trust for Redemption of Class B Common Shares4596,69Current Portion of Capital Lease Obligation7,49025,711Due to Shareholders262,500262,400Liabilities, Current, Total916,053622,400Copital Lease Obligation, net of current portion1266,30Copital Lease Obligation, net of current portion916,053625,033Commitments and Contingent Liabilities916,053625,033Preferred stock; par value \$.0001 per share; 5,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2011 respectively540	Liabilities and Equity		
Funds Held in Trust for Redemption of Class B Common Shares4Current Portion of Capital Lease Obligation7,49025,71Due to Shareholders262,500262,400Liabilities, Current, Total916,0536622,400Long Term Liabilities916,0536622,003Copital Lease Obligation, net of current portion026,533Total Liabilities916,053625,033Commitments and Contingent Liabilities916,053625,033Preferred stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2011 respectively540	Current Liabilities		
Funds Held in Trust for Redemption of Class B Common Shares4Current Portion of Capital Lease Obligation7,49025,71Due to Shareholders262,500262,400Liabilities, Current, Total916,053622,400Long Term Liabilities916,053622,603Copital Lease Obligation, net of current portion916,053625,033Total Liabilities916,053625,033Commitments and Contingent Liabilities916,053625,033Equity916,053625,033Preferend stock; par value \$.0001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31,2011 respectively540	Accounts Payable and Accrued Expenses	646,059	596,692
Due to Shareholders262,500Liabilities, Current, Total916,053622,400Long Term Liabilities216,053625,030Capital Lease Obligation, net of current portion916,053625,033Total Liabilities916,053625,033Commitments and Contingent Liabilities916,053625,033EquityPreferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2011 respectively540		4	2
Liabilities, Current, Total916.053622.40Long Term Liabilities916.053622.40Capital Lease Obligation, net of current portion2,63Total Liabilities916.053625.03Commitments and Contingent Liabilities916.053EquityPreferred stock; par value \$.0001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2011 respectively540	Current Portion of Capital Lease Obligation	7,490	25,711
Long Term LiabilitiesSecond Second Secon	Due to Shareholders	262,500	
Capital Lease Obligation, net of current portion2,63Copital Lease Obligation, net of current portion2,63Total Liabilities916,053Commitments and Contingent Liabilities0EquityPreferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October540Common stock; par value \$.0001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540	Liabilities, Current, Total	<u>916,053</u>	622,407
Total Liabilities916,053625,03Commitments and Contingent LiabilitiesEquity </td <td>Long Term Liabilities</td> <td></td> <td></td>	Long Term Liabilities		
Commitments and Contingent LiabilitiesImage: Commitments and Contingent LiabilitiesEquityPreferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October 31, 2011Image: Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540	Capital Lease Obligation, net of current portion		2,630
Equity Preferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October 31, 2011 Image: Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively 540	Total Liabilities	<u>916,053</u>	<u>625,037</u>
Preferred stock; par value \$.0001 per share, 5,000,000 shares authorized, 1 issued and outstanding as at July 31, 2012 and October 31, 2011Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540	Commitments and Contingent Liabilities		
31, 2011Common stock; par value \$.00001 per share; 65,000,000 shares authorized, 31,449,239 and 31,237,262 common shares and 24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively540	Equity		
24,176,927 and 24,388,904 exchangeable shares issued and outstanding as at July 31, 2012 and October 31, 2011 respectively			
Additional paid-in capital 41,774,001 41,774,001		540	540
	Additional paid-in capital	41,774,001	41,774,001

Deficit accumulated during development stage	(41,675,280)	(40,731,174)
Accumulated other comprehensive loss	(159,491)	(173,407)
Total CardioGenics Holdings Inc. equity	(60,230)	<u>869,960</u>
Non-controlling interest	(335,348)	(329,524)
Total equity (deficiency)	<u>(395,578)</u>	<u>540,436</u>
Total liabilities and equity	<u>\$ 520,475</u>	<u>\$ 1,165,473</u>

Condensed Consolidated Balance Sheets (Parenthetical)

Condensed Consolidated Balance Sheets (Parenthetical) (USD \$)	07/31/2012	10/31/2011
Exchangeable Shares [Member]		
Common stock, common shares issued	24,176,927	24,388,904
Common stock, common shares outstanding	24,176,927	24,388,904
Common Stock [Member]		
Common stock, common shares issued	31,449,239	31,237,262
Common stock, common shares outstanding	31,449,239	31,237,262
Preferred Stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	1	1
Preferred stock, outstanding	1	1
Common stock, par value	\$ 0.00001	\$ 0.00001
Common stock, shares authorized	65,000,000	65,000,000

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (USD \$)	3 Months Ended 07/31/2012	9 Months Ended 07/31/2012	9 Months Ended 07/31/2011	07/31/2012	3 Months Ended 07/31/2011
Accumulated Deficit During Development Stage [Member]					
Net Loss attributable to CardioGenics Holdings Inc.		<u>\$ (944,106)</u>			
Noncontrolling Interest [Member]					
Net Loss attributable to non-controlling interest		(5,824)			
Revenue		1,136	6,400	10,012	6,400
Operating Expenses					
Depreciation of Property and Equipment	4,541	13,635	14,938	215,074	5,409
Amortization of Patent Application Costs	1,215	3,775	3,222	16,186	1,090
Write-off of Patent Application Costs				214,625	
General and Administrative	154,869	516,357	958,963	8,105,047	278,314
Write-off of Goodwill				12,780,214	
Research and Product Development, Net of Investment Tax Credits	73,715	422,453	534,776	4,136,211	141,206
Cost of Settlement of Lawsuit			1,753,800	1,753,800	1,753,800
Total operating expenses	234,340	<u>956,220</u>	3,265,699	27,221,157	<u>2,179,819</u>
Operating Loss	(234,340)	<u>(955,084)</u>	(3,259,299)	(27,211,145)	(2,173,419)
Other Expenses (Income)					
Interest Expense and Bank Charges, Net	5,402	14,887	15,340	2,151,523	6,440
Loss on Change in Value of Derivative Liability				12,421,023	
Loss (Gain) on Foreign Exchange Transactions	(915)	(20,041)	139,312	189,224	7,149
Total other expenses (income)	4,487	<u>(5,154)</u>	<u>154,652</u>	<u>14,761,770</u>	<u>13,589</u>
Loss from Continuing Operations	(238,827)	<u>(949,930)</u>	<u>(3,413,951)</u>	<u>(41,972,915)</u>	(2,187,008)
Discontinued Operations					
Gain on Sale of Subsidiary				90,051	
Loss from Discontinued Operations				(127,762)	
Net Loss	(238,827)	<u>(949,930)</u>	<u>(3,413,951)</u>	(42,010,626)	<u>(2,187,008)</u>
Net Loss attributable to non-controlling interest	(1,393)	(5,824)	(22,850)	(335,348)	(14,638)
Net Loss attributable to CardioGenics Holdings Inc.	<u>\$ (237,434)</u>	<u>\$ (944,106)</u>	<u>\$ (3,391,101)</u>	<u>\$ (41,675,278)</u>	<u>\$ (2,172,370)</u>
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders	\$ (0.01)	\$ (0.02)	\$ (0.06)		\$ (0.04)
Weighted-average shares of Common Stock outstanding	55,626,166	55,626,166	54,256,408		54,626,166

Condensed Consolidated Statements of Changes in Equity

Accumulated Deficit During Development Stage [Member]Signal statusBeginning Balance\$(40,731,174)[Comprehensive Income (Loss):(41,675,280)Net Loss(41,675,280)Accumulated Other Comprehensive Income [Member](1173,407)Beginning Balance(1173,407)Other Comprehensive Income(1159,491)Aditional Paid In Capital [Member](159,491)Additional Paid In Capital [Member](159,491)Beginning Balance41,774,001Common Stock [Member]41,774,001Beginning Balance (in shares)55,626,166Ending Balance (in shares)5,626,166Ending Balance (in shares)5,626,166Ending Balance (in shares)5,626,166Ending Balance (in shares)5,626,166Ending Balance(312,324)Net Loss attributable to onocontrolling interest(335,348)Beginning Balance5,824Net Loss attributable to onocontrolling interest(335,348)Beginning Balance5,824Net Loss(94,104) - (1,57,278)	Condensed Consolidated Statements of Changes in Equity (USD \$)	9 Months Ended 07/31/2012	07/31/2012
Comprehensive Income (Loss): (41,675,280) Net Loss (41,675,280) Ending Balance (41,675,280) Accumulated Other Comprehensive Income [Member] (173,407) Beginning Balance (173,407) Other Comprehensive Income (159,491) Additional Paid In Capital [Member] (159,491) Beginning Balance 41,774,001 Currency Translation Adjustment 41,774,001 Additional Paid In Capital [Member] 41,774,001 Beginning Balance 41,774,001 Common Stock [Member] 55,626,166 Beginning Balance (in shares) 55,626,166 Ending Balance 540 Noncontrolling Interest [Member] 540 Beginning Balance (335,348) Reginning Balance (335,348) Reginning Balance (335,348) Reginning Balance (5,824) Net loss attributable to noncontrolling interest (5,824) <	• • •		
Net Loss (944,106) (944,106) Ending Balance (41,675,280) (41,675,280) Accumulated Other Comprehensive Income [Member] (173,407) (173,407) Beginning Balance (173,407) (159,491) Other Comprehensive Income (159,491) (159,491) Additional Paid In Capital [Member] (173,407) (159,491) Common Stock [Member] (173,407) (173,407) Beginning Balance (173,407) (173,407) Common Stock [Member] (173,407) (173,407) Beginning Balance (in shares) (55,626,166) (56,626,166) Ending Balance (320,516) (540) Net loss attributable to noncontrolling interest (5,824) (335,348) <t< td=""><td>Beginning Balance</td><td>\$ (40,731,174)</td><td></td></t<>	Beginning Balance	\$ (40,731,174)	
Interface (C11,111) Ending Balance (41,675,280) Accumulated Other Comprehensive Income [Member] (41,675,280) Beginning Balance (173,407) Other Comprehensive Income (13,916) Currency Translation Adjustment 13,916 Ending Balance (159,491) Additional Paid In Capital [Member] (159,491) Additional Paid In Capital [Member] (41,774,001) Beginning Balance (41,774,001) Common Stock [Member] (41,774,001) Beginning Balance (in shares) 55,626,166 Ending Balance (329,524) (540) Noncontrolling Interest [Member] (335,348) (335,348) Beginning Balance (335,348) (335,348) Beginning Balance (5,824) (335,348) Beginning Balance (5,824) (335,348) Beginning Balance (5,82	Comprehensive Income (Loss):		
Accumulated Other Comprehensive Income [Member]Beginning Balance(173,407)Other Comprehensive Income(173,407)Other Comprehensive Income(159,491)Currency Translation Adjustment13,916Ending Balance(159,491)Additional Paid In Capital [Member]41,774,001Beginning Balance41,774,001Common Stock [Member]1Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance5400Noncontrolling Interest [Member]13,916Beginning Balance(335,348)Beginning Balance(335,348)Inding Balance540,436Noncontrolling Interest [Member](335,348)Beginning Balance(335,348)Inding Balance540,436Net loss attributable to noncontrolling interest(5,824)Inding Balance540,436Net loss attributable to noncontrolling interest(5,824)Inding Balance540,436Met Loss(944,106) <ttr>Currency Translation Adjustment13,916Currency Translation Adjustment13,916Currency Translation Adjustment(930,190)Yend Comprehensive (Loss)(930,190)</ttr>	Net Loss	(944,106)	
Beginning Balance(173,407)Other Comprehensive Income(173,407)Currency Translation Adjustment13,916Ending Balance(159,491)Additional Paid In Capital [Member](159,491)Beginning Balance41,774,001Ending Balance41,774,001Common Stock [Member]1Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance5400Noncontrolling Interest [Member]13,916Beginning Balance(335,348)Beginning Balance(335,348)Reginning Balance(335,348)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Comprehensive Income (Loss):13,916Net Loss(944,106) Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Ending Balance	(41,675,280)	(41,675,280)
Other Comprehensive IncomeImage: Comprehensive IncomeCurrency Translation Adjustment13,916Ending Balance(159,491)Additional Paid In Capital [Member]Beginning Balance41,774,001Ending Balance41,774,001Common Stock [Member]41,774,001Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]13,916Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Met Loss(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Currency Translation Adjustment(930,190)	Accumulated Other Comprehensive Income [Member]		
Currency Translation Adjustment 13,916 Ending Balance (159,491) Additional Paid In Capital [Member] 41,774,001 Beginning Balance 41,774,001 Ending Balance 41,774,001 Common Stock [Member] 41,774,001 Beginning Balance (in shares) 55,626,166 Beginning Balance (in shares) 55,626,166 Ending Balance 55,626,166 Ending Balance 55,626,166 Stopped (in shares) 55,626,166 Ending Balance 55,626,166 Stopped (in shares) (329,524) Net loss attributable to noncontrolling interest (5,824) Net loss (Beginning Balance	(173,407)	
Ending Balance(159,491)(159,491)Additional Paid In Capital [Member]Beginning Balance41,774,001Ending Balance41,774,001Common Stock [Member]Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Stop (329,524)55,626,166Ending Balance(329,524)Noncontrolling Interest [Member](335,348)Beginning Balance(335,348)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Inding Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Other Comprehensive Income		
Additional Paid In Capital [Member]Beginning Balance41,774,001Ending Balance41,774,001Common Stock [Member]41,774,001Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)540Noncontrolling Interest [Member]540Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Comprehensive Income (Loss):(944,106) Net Loss(944,106) Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Currency Translation Adjustment	13,916	
Beginning Balance41,774,001Ending Balance41,774,001Common Stock [Member]41,774,001Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]540Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Cumrency Income (Loss):13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Ending Balance	(159,491)	(159,491)
Ending Balance41,774,001Common Stock [Member]55,626,166Beginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]540Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance540,436Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Additional Paid In Capital [Member]		
Common Stock [Member]StraigBeginning Balance (in shares)55,626,166Beginning Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance (in shares)540Noncontrolling Interest [Member]540Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance540,436Net loss attributable to noncontrolling interest540,436Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Met loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(14,075,278)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Beginning Balance	41,774,001	
Beginning Balance (in shares)55,626,166Beginning Balance540Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]540Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance540,436Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Reginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Ending Balance	41,774,001	41,774,001
Beginning Balance540Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Inding Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(342,106) (41,675,278)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Common Stock [Member]		
Ending Balance (in shares)55,626,166Ending Balance (in shares)55,626,166Ending Balance540Noncontrolling Interest [Member]1329,524Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Beginning Balance (in shares)	55,626,166	
Ending Balance540540Noncontrolling Interest [Member]Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Interest Income (Loss):(335,348)Net Loss(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Beginning Balance	540	
Noncontrolling Interest [Member]Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Comprehensive Income (Loss):(41,675,278)Net Loss(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Ending Balance (in shares)	55,626,166	55,626,166
Beginning Balance(329,524)Net loss attributable to noncontrolling interest(5,824)Ending Balance(335,348)Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(5,824)Net loss attributable to noncontrolling interest(335,348)Comprehensive Income (Loss):(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Ending Balance	540	540
Net loss attributable to noncontrolling interest(5,824)Ending Balance(335,348)(335,348)Beginning Balance540,436(335,348)Net loss attributable to noncontrolling interest(5,824)(335,348)Comprehensive Income (Loss):Net Loss(944,106) (41,675,278)Other Comprehensive IncomeCurrency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Noncontrolling Interest [Member]		
Ending Balance(335,348)(335,348)Beginning Balance540,436540,436Net loss attributable to noncontrolling interest(5,824)(335,348)Comprehensive Income (Loss):Net Loss(944,106) (41,675,278)Other Comprehensive IncomeCurrency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Beginning Balance	(329,524)	
Beginning Balance540,436Net loss attributable to noncontrolling interest(5,824)(335,348)Comprehensive Income (Loss):(944,106)(41,675,278)Net Loss(944,106)(41,675,278)Other Comprehensive Income13,916(10,100)Currency Translation Adjustment13,916(10,100)Total Comprehensive (Loss)(930,190)(10,100)	Net loss attributable to noncontrolling interest	(5,824)	
Net loss attributable to noncontrolling interest(5,824)(335,348)Comprehensive Income (Loss):(944,106)(41,675,278)Other Comprehensive Income13,91613,916Currency Translation Adjustment13,91613,916Total Comprehensive (Loss)(930,190)1000	Ending Balance	(335,348)	(335,348)
Comprehensive Income (Loss):Net Loss(944,106) (41,675,278)Other Comprehensive Income13,916Currency Translation Adjustment13,916Total Comprehensive (Loss)(930,190)	Beginning Balance	540,436	
Net Loss (944,106) (41,675,278) Other Comprehensive Income 13,916 Currency Translation Adjustment 13,916 Total Comprehensive (Loss) (930,190)	Net loss attributable to noncontrolling interest	(5,824)	(335,348)
Other Comprehensive Income Currency Translation Adjustment 13,916 Total Comprehensive (Loss)	Comprehensive Income (Loss):		
Currency Translation Adjustment 13,916 Total Comprehensive (Loss) (930,190)	Net Loss	(944,106)	(41,675,278)
Total Comprehensive (Loss) (930,190)	Other Comprehensive Income		
	Currency Translation Adjustment	13,916	
Ending Balance \$ (395,578) \$ (395,578)	Total Comprehensive (Loss)	(930,190)	
	Ending Balance	\$ (395,578)	\$ (395,578)

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows (USD \$)	9 Months Ended 07/31/2012	9 Months Ended 07/31/2011	07/31/2012
Settlement Of Litigation 1 [Member]			
Adjustments to reconcile net loss for the period to net cash used in operating activities			
Common Stock and Warrants issued			\$ 1,653,800
Goods And Services Exchanged For Equity Instrument [Member]			
Adjustments to reconcile net loss for the period to net cash used in operating activities			
Common Stock and Warrants issued		100,000	2,726,262
Stock Options Issued			192,238
Management [Member]			
Adjustments to reconcile net loss for the period to net cash used in operating activities			
Stock Options Issued			54,582
Cash flows from operating activities			
Net Loss for the Period	(949,930)	(3,413,951)	(42,010,626)
Adjustments to reconcile net loss for the period to net cash used in operating activities			
Depreciation of Property and Equipment	13,635	14,938	215,074
Amortization of Patent Application Costs	3,775	3,222	16,186
Write-off of Patent Application Costs			214,625
Write-off of Goodwill			12,780,214
Amortization of Deferred Debt Issuance Costs			511,035
Loss on Extinguishment of Debt			275,676
Loss on Change in Value of Derivative Liability			12,421,023
Interest Accrued and Foreign Exchange Loss on Debt			922,539
Unrealized Foreign Currency Exchange Gains			25,092
Beneficial Conversion Charge included in Interest Expense			452,109
Re-pricing of Options for Services Rendered		163,750	163,750
Common Stock Issued as Employee or Officer/Director Compensation			2,508,282
Stock Options Issued	0	0	
Changes in Operating Assets and Liabilities, Net of Acquisition			
Accounts Receivable	8,746	(6,400)	(256)
Share Subscriptions Receivable		115,000	
Deposits and Prepaid Expenses	319	38,673	(50,433)
Refundable Taxes Receivable	(1,043)	(16,101)	(35,370)
Investment Tax Credits Receivable	31,320	156,482	(136,115)
Accounts Payable and Accrued Expenses	49,370	1,835,883	(121,850)
Advances			131
Cash used in operating activities	(843,808)	(1,008,504)	(7,222,032)
Cash flows from investing activities			
Cash Acquired from Acquisition			195,885
Purchase of Property and Equipment	(3,893)	(12,772)	(223,559)
Patent Application Costs	(4,329)		(318,899)
Cash used in investing activities	(8,222)	(12,772)	(346,573)
Cash flows from financing activities			
Repayment of Capital Lease Obligations	(20,851)	(5,139)	(36,427)

Source: CardioGenics Holdings Inc., 10-Q, September 14, 2012

Powered by Morningstar[®] Document ResearchSM

Due to Shareholders	262,500		262,500
Due to Director		(15,149)	725,330
Issue of Debentures			1,378,305
Issue of Common Shares on Exercise of Stock options		2,750	2,781
Issue of Common Shares on Exercise of Warrants			45,652
Issue of Common Shares for Cash		359,411	5,624,169
Refund of Share Subscription		(15,378)	(15,000)
Redemption of 10% Senior Convertible Debentures			(394,972)
Cash provided by financing activities	241,649	326,495	<u>7,592,338</u>
Effect of foreign exchange on cash and cash equivalents	13,911	(32,327)	48,999
Cash and Cash Equivalents			
Increase (decrease) in cash and cash equivalents during the period	(596,470)	(727,108)	72,732
Beginning of Period	669,202	1,844,752	
End of Period	\$ 72,732	\$ 1,117,644	\$ 72,732

Nature of Business	9 Months Ended
(USD \$)	07/31/2012

Nature of Business 1.Nature of Business

CardioGenics Inc. ("CardioGenics") was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics' business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings Inc.

Basis of Presentation 9 Months Ended (USD \$) 07/31/2012

Basis of Presentation 2.Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States ("US GAAP") as of July 31, 2012, its results of operations for the three and nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012, changes in equity for the nine months ended July 31, 2012 and cash flows for the nine months ended July 31, 2012 and 2011, and the period from November 20, 1997 (date of inception) to July 31, 2012. CardioGenics Holdings Inc and its subsidiaries are referred to together herein as the "Company". Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2011 and 2010 (the "Audited Financial Statements") included in the Company's Form 10-K/A that was previously filed with the SEC on April 13, 2012 and from which the October 31, 2011 consolidated balance sheet was derived.

The results of the Company's operations for the three and nine months ended July 31, 2012 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2012.

The condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2012 of approximately \$41.7 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management's plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary of Significant Accounting Policies.

Summary of Significant Accounting Policies. (USD \$)	9 Months Ended 07/31/2012
Summary of Significant Accounting Policies.	3.Summary of Significant Accounting Policies.
	Recent Accounting Pronouncements In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210):

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

	9 Months Ended 07/31/2012
Income Taxes	4.Income Taxes

Based on the Company's evaluation, management has concluded that there are no significant tax reserves requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2012, approximated \$6,362,000 (2011 - \$5,495,000) which will expire from 2013 through 2032. All fiscal years have been assessed as originally filed in Canadian jurisdictions.

As of July 31, 2012, the Company had net operating loss carryforwards from US sources of approximately \$40,647,000 available to reduce future US Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2011 are yet to be filed.

For the nine months ended July 31, 2012 and 2011, the Company's effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

Due to Shareholders	9 Months Ended
(USD \$)	07/31/2012

Due to Shareholders 5.Due to Shareholders

In February 2012 the Company received \$262,500 for the subscription of 1,050,000 of the Company's common stock. To date, the common stock has not been issued to the subscribers.

Stock Based Compensation 9 Months Ended 07/31/2012

Stock Based Compensation 6.Stock Based Compensation

Stock-based employee compensation related to stock options for the nine months ended July, 2012 and 2011 amounted to \$-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

	Options	Weighted Average Exercise Price
Outstanding – October 31, 2010	305,000	\$ 2.34
Granted	_	_
Forfeited/Expired	_	_
Exercised	275,000	\$ 0.01
Outstanding – October 31, 2011	30,000	\$ 0.90
Granted	_	_
Forfeited/Expired	_	_
Exercised	_	_
Outstanding – July 31, 2012	30,000	\$ 0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2012.

Warrants 9 Months Ended (USD \$) 07/31/2012

Warrants 7.Warrants

Outstanding warrants are as follows:

_	July 31, 2012	October 31, 2011
Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to subscribers to the debenture financing of 2004 and its related extension entitling the holder	_	2,046,808
to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including	_	1,021,654
July 31, 2012 expired unexercised	-	208,417
Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Company	_	136,220
at an exercise price of \$0.90 per share up to and including July 31, 2012 expired unexercised	_	104,785
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of \$0.90 per common share up to and including July 31, 2017 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to	287,085	287,085
purchase 1 common share in the Company at an exercise price of \$0.30 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to	250,000	250,000
purchase 1 common share in the Company at an exercise price of \$0.50 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to	250,000	250,000
purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$1.00 per common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to	500,000	500,000
purchase 1 common share in the Company at an exercise price of \$0.75 per common share up to and including August 23, 2016	500,000	500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.10 per common share up to and including March 20, 2013	1,500,000	1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.34 per common share up to and including March 20, 2013 Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the	1,500,000	1,500,000
Company at an exercise price of \$0.50 per common share up to and including March 20, 2013	1,000,000	1,000,000
Total Warrants outstanding	6,287,085	9,804,969

Issuance of Common Stock

Issuance of Common Stock 9 Months Ended 07/31/2012

Issuance of Common Stock 8.Issuance of Common Stock

During the nine months ended July 31, 2012, the Company issued no common shares, except for 211,977 common shares which were issued in exchange for 211,977 exchangeable shares.

Net Loss per Share	9 Months Ended
(USD \$)	07/31/2012

Net Loss per Share 9.Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Month July 3		Nine Month July 3	
	2012	2011	2012	2011
Weighted-average shares - basic Effect of dilutive securities	55,626,166	54,626,166	55,626,166	54,256,408
Weighted-average shares - diluted	55,626,166	54,626,166	55,626,166	54,256,408

Basic EPS and diluted EPS for the three and nine months ended July, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 6,317,085 and 4,131,974 incremental shares respectively have been excluded from the nine months ended July 31, 2012 and 2011 computation of diluted EPS as they are antidilutive given the net losses generated.

Commitments and Contingent Liabilities

Commitments and Contingent Liabilities (USD \$)	9 Months Ended 07/31/2012
Commitments and Contingent Liabilities	10.Commitments and Contingent Liabilities

Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of \$514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

Supplemental Disclosure of Cash Flow Information

Supplemental Disclosure of Cash Flow Information (USD \$)	9 Months Ended 07/31/2012
Supplemental Disclosure of Cash Flow Information	11.Supplemental Disclosure of Cash Flow Information

]	For the Nine Months Ended July 31		
	_	2012		2011
Cash pai during the yea for:				
Interest Income	\$	11,420	\$	7,480
taxes	\$	_	\$	_

Summary of Significant Accounting Policies. (Policies)

Summary of Significant Accounting Policies. (Policies) (USD \$)	9 Months Ended 07/31/2012
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.
	In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under this ASU, an entity will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. Early adoption is permitted. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

Stock Based Compensation (Tables)

	9 Months Ended 07/31/2012
Summary of Common Stock Options Granted, Forfeited or Expired and Exercised under Plan	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

	Options	Av Ex	eighted verage xercise Price
Outstanding - October 31,			
2010	305,000	\$	2.34
Granted	_		—
Forfeited/Expired	_		—
Exercised	275,000	\$	0.01
Outstanding - October 31,			
2011	30,000	\$	0.90
Granted	_		_
Forfeited/Expired	_		_
Exercised	_		_
Outstanding - July 31, 2012	30,000	\$	0.90

Warrants (Tables)

Warrants (Tables) (USD \$)	9 Months Ended 07/31/2012		
Warrants Outstanding		July 31, 2012	October 31, 2011
	Issued to subscribers to the debenture financing of 2003 and its related extension entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to subscribers to the debenture financing of 2004 and its related extension entitling	_	2,046,808
	the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to agents for the debenture financings of 2003 and 2004 entitling the holder to	_	1,021,654
	purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired unexercised Issued to former employee entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.47 per common share up to and including July 31, 2012 expired	-	208,417
	unexercised Issued to consultants July 31, 2009, entitling the holder to purchase 1 common share of the Company at an exercise price of \$0.90 per share up to and including July 31, 2012	-	136,220
	expired unexercised Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of \$0.90 per common share up to and including July 31,	-	104,785
	2017 Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.30 per	287,085	287,085
	common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.50 per	250,000	250,000
	common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$0.75 per	250,000	250,000
	common share up to and including August 23, 2016 Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of \$1.00 per	500,000	500,000
	common share in the Company at an exercise price of \$1.00 per common share in the Company at an exercise price of \$1.00 per common share in the Company at an exercise price of \$0.75 per common share in the Company at an exercise price of \$0.75 per	500,000	500,000
	common share up to and including August 23, 2016 Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of \$0.10 per common share up to and including March	500,000	500,000
	20, 2013 Issued to consultants in September 2011 entitling the holders to purchase 1 common share in	1,500,000	1,500,000
	the Company at an exercise price of \$0.34 per common share up to and including March 20, 2013 Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company of \$0.60 per common share in the discrete state of the second state of \$0.60 per common share to end including March	1,500,000	1,500,000
	the Company at an exercise price of \$0.50 per common share up to and including March 20, 2013	1,000,000	1,000,000
	Total Warrants outstanding	6,287,085	9,804,969

Net Loss per Share (Tables)

9 Months Ended 07/31/2012 Net Loss per Share (Tables) (USD \$) The following table sets forth the computation of weighted-average shares outstanding for

Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share

calculating basic and diluted earnings per share (EPS):

	Three Months Ended July 31,		Nine Months Ended July 31,	
	2012	2011	2012	2011
Weighted-average shares - basic Effect of dilutive securities	55,626,166	54,626,166	55,626,166	54,256,408
Weighted-average shares - diluted	55,626,166	54,626,166	55,626,166	54,256,408

Supplemental Disclosure of Cash Flow Information (Tables)

Supplemental Disclosure of Cash Flow Information (Tables) (USD \$)	9 Months Ended 07/31/2012	
Cash Flow Supplemental Disclosures	For the Nine Mo July 3 2012	
	Cash paid during the year for: Inter & st 11,420 Income taxes\$ —	\$ 7,480 \$ —

Nature of Business - Additional Information (Detail)

Nature of Business - Additional Information (Detail) (USD \$)	9 Months Ended 07/31/2012
Entity incorporation date	1997-11-20
Place of entity incorporated	Ontario, Canada

Basis of Presentation - Additional Information (Detail)



Deficit accumulated during development \$41,675,280 \$40,731,174 stage

Income Taxes - Additional Information (Detail)

Income Taxes - Additional Information (Detail) (USD \$)	9 Months Ended 07/31/2012	9 Months Ended 07/31/2011
CA		
Net operating loss carry forwards	\$ 6,362,000	\$ 5,495,000
Operating loss carry forwards expiration period	2013 through 2032	2013 through 2032
US		
Net operating loss carry forwards	\$ 40,647,000	
Operating loss carry forwards expiration period	2019 through 2032	

Due to Shareholders - Additional Information (Detail)

Due to Shareholders - Additional Information (Detail) (USD \$)	1 Months Ended 02/29/2012
Cash received for the subscription of common stock	\$ 262,500
Number of shares issuable to subscribers	1,050,000

Stock Based Compensation - Additional Information (Detail)

Stock Based Compensation - Additional Information (Detail) (USD \$)	07/31/2012
Goods And Services Exchanged For Equity Instrument [Member]	
Stock Options Issued	\$ 192,238
Management [Member]	
Stock Options Issued	\$ 54,582
Stock Options Issued	

Summary of Common Stock Options Granted, Forfeited or Expired and Exercised under Plan (Detail)

Summary of Common Stock Options Granted, Forfeited or Expired and Exercised under Plan (Detail) (USD \$)	9 Months Ended 07/31/2012	12 Months Ended 10/31/2011
Options		
Outstanding beginning balance	30,000	305,000
Granted		
Forfeited/Expired		
Exercised		275,000
Outstanding ending balance	30,000	30,000
Weighted Average Exercise Price		
Beginning balance	\$ 0.90	\$ 2.34
Granted		
Forfeited/Expired		
Exercised		\$ 0.01
Ending balance	\$ 0.90	\$ 0.90

Warrants Outstanding (Detail)

Warrants Outstanding (Detail) (USD \$)	07/31/2012	10/31/2011
Transaction Eight [Member]		
Warrants outstanding	250,000	250,000
Transaction Eleven [Member]		
Warrants outstanding	500,000	500,000
Transaction Fifteen [Member]		
Warrants outstanding	1,000,000	1,000,000
Transaction Five [Member]		
Warrants outstanding		104,785
Transaction Four [Member]		
Warrants outstanding		136,220
Transaction Nine [Member]		
Warrants outstanding	500,000	500,000
Transaction One [Member]		
Warrants outstanding		2,046,808
Transaction Seven [Member]		
Warrants outstanding	250,000	250,000
Transaction Six [Member]		
Warrants outstanding	287,085	287,085
Transaction Ten [Member]		
Warrants outstanding	500,000	500,000
Transaction Thirteen [Member]		
Warrants outstanding	1,500,000	1,500,000
Transaction Three [Member]		
Warrants outstanding		208,417
Transaction Twelve [Member]		
Warrants outstanding	1,500,000	1,500,000
Transaction Two [Member]		
Warrants outstanding		1,021,654
Warrants outstanding	6,287,085	9,804,969

Warrants Outstanding (Parenthetical) (Detail)

Warrants Outstanding (Parenthetical) (Detail) (USD \$)	9 Months Ended 07/31/2012	12 Months Ei 10/31/2011	nded
Transaction Eight [Member]			
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.50		0.50
Warrant, last exercisable date	2016-08-23	2016-08-23	
Transaction Eleven [Member]			
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.75		0.75
Warrant, last exercisable date	2016-08-23	2016-08-23	
Transaction Fifteen [Member]			
Warrant, issuance date	2011-09	2011-09	
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.50		0.50
Warrant, last exercisable date	2013-03-20	2013-03-20	
Transaction Five [Member]			
Warrant, issuance date		2009-07-31	
Warrant, exchange ratio to common stock			1
Warrant, exercise price			0.90
Warrant, last exercisable date		2012-07-31	
Transaction Four [Member]			
Warrant, exchange ratio to common stock			1
Warrant, exercise price			0.47
Warrant, last exercisable date		2012-07-31	
Transaction Nine [Member]			
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.75		0.75
Warrant, last exercisable date	2016-08-23	2016-08-23	
Transaction One [Member]			
Warrant, exchange ratio to common stock			1
Warrant, exercise price			0.47
Warrant, last exercisable date		2012-07-31	
Transaction Seven [Member]			
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.30		0.30
Warrant, last exercisable date	2016-08-23	2016-08-23	
Transaction Six [Member]			
Warrant, issuance date	2009-08-01	2009-08-01	
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.9		0.9
Warrant, last exercisable date	2017-07-31	2017-07-31	
Transaction Ten [Member]			

Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	1		1
Warrant, last exercisable date	2016-08-23	2016-08-23	
Transaction Thirteen [Member]			
Warrant, issuance date	2011-09	2011-09	
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.34		0.34
Warrant, last exercisable date	2013-03-20	2013-03-20	
Transaction Three [Member]			
Warrant, exchange ratio to common stock			1
Warrant, exercise price			0.47
Warrant, last exercisable date		2012-07-31	
Transaction Twelve [Member]			
Warrant, issuance date	2011-09	2011-09	
Warrant, exchange ratio to common stock	1		1
Warrant, exercise price	0.10		0.10
Warrant, last exercisable date	2013-03-20	2013-03-20	
Transaction Two [Member]			
Warrant, exchange ratio to common stock			1
Warrant, exercise price			0.47
Warrant, last exercisable date		2012-07-31	

Issuance of Common Stock - Additional Information (Detail)

	9 Months Ended 07/31/2012
Exchangeable Shares [Member]	
Shares issued upon exchange of exchangeable shares	211,977

Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Detail)

Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Detail) (USD \$)	Ended	Ended	Ended	9 Months Ended 07/31/2011
Weighted-average shares - basic	55,626,166	54,626,166	55,626,166	54,256,408
Effect of dilutive securities				
Weighted-average shares - diluted	55,626,166	<u>54,626,166</u>	<u>55,626,166</u>	54,256,408

Net Loss Per Share - Additional Information (Detail)

Net Loss Per Share - Additional Information (Detail) (USD \$)	9 Months Ended 07/31/2012	9 Months Ended 07/31/2011
Incremental shares excluded from computation of diluted earning per share	6,317,085	4,131,974

Commitments and Contingent Liabilities - Additional Information (Detail)

Commitments and Contingent Liabilities - Additional	1 Months
Information	Ended
(Detail) (USD \$)	04/22/2009
	¢ 514.00

Former employee related claims

\$ 514,000

Supplemental Disclosure of Cash Flow Information (Detail)

Supplemental Disclosure of Cash Flow Information (Detail) (USD \$)	Ended	9 Months Ended 07/31/2011
Cash paid during the year for:		
Interest	\$ 11,420	\$ 7,480

Income taxes

Created by Morningstar[®] Document Research[™] http://documentresearch.morningstar.com